CD4 and B-cell non-Hodgkin lymphoma: In fact, preclinical studies in xenogeneic animal models of B-cell lymphoma have shown increased antitumor effect of CAR19 T cells with a defined composition of CD4:CD8 ratios (e.g., ratio 1:1).